Global Knee Implants Market to Exceed USD 7 Bn by 2021, States DPI Research in Its New Report Recently Added at MarketPublishers.com

The future outlook for the world’s knee implants market looks promising due to ongoing advances in computer-assisted total knee implants and also other technological platforms. The continued market growth will likely be supported by aging global population, rising demand for knee replacement procedures, enhancing heath awareness, rise in consumers’ spending capacity, amid other factors. The

Global POCT Market to Reach USD 38 Bn by 2022, According to DPI Research in Its New Report Available at MarketPublishers.com

The dynamic of point-of–care testing (POCT), or bedside testing, is designed to bring medical diagnostic testing nearer to the patient. POCT facilitates to inform faster, immediate decisions for clinical management of the patient in physicians’ offices, hospitals, ambulances, patients’ homes, and in the field. The worldwide POCT market is forecast to reach USD 38 billion by

High–Intensity Focused Ultrasound Therapy Grew in Popularity, According to New DPI Research Report Available at MarketPublishers.com

Recent advancements in high–intensity focused ultrasound (HIFU) have raised its popularity. In clinics, HIFU has been used in the treatment of a diversity of solid malignancies in a clearly defined volume, comprising the liver, pancreas, prostate, uterine fibroids, breast, and soft–tissue sarcomas. By contrast with traditional tumour/cancer treatment modes, like open surgery, radiotheraphy and chemotherapy,

Neurovascular Intervention Market to Amount to USD 4 Billion by 2022, Forecasts DPI Research in Its New Report Available at MarketPublishers.com

Increasing prevalence of the cerebrovascular disease along with risk factors associated with it, population ageing and establishment of appropriate reimbursement are some of factors encouraging growth of the neurovascular intervention marketplace. As a result, this market is expected to reach a value of approximately USD 4 billion by 2022. The value will be higher if

The global neuromodulation market is anticipated to hit more than $5 billion by 2020, according to a WiseGuyReports analysis.

http://www.beckersspine.com/orthopedic-a-spine-device-a-implant-news/item/33518-medtronic-boston-scientific-lead-neuromodulation-market-8-observations.html The global neuromodulation market is anticipated to hit more than $5 billion by 2020, according to a WiseGuyReports analysis. Here are eight observations: 1. An increasing geriatric population and a growing number of neurological disease cases are spurring market growth. 2. Also, development of more minimally invasive techniques will boost the market. 3. The

Medtronic, Boston Scientific lead neuromodulation market: 8 observations

http://www.beckersspine.com/orthopedic-a-spine-device-a-implant-news/item/33518-medtronic-boston-scientific-lead-neuromodulation-market-8-observations.html The global neuromodulation market is anticipated to hit more than $5 billion by 2020, according to a WiseGuyReports analysis. Here are eight observations: 1. An increasing geriatric population and a growing number of neurological disease cases are spurring market growth. 2. Also, development of more minimally invasive techniques will boost the market. 3. The

Neurovascular Intervention Market Size – DPI Research

The Global market for Neurovascular Intervention is projected to reach nearly US$4 Billion by the end of 2021 growing at a CAGR of around XX% from 2016 to 2021. Market growth can be attributed to factors such as rising prevalence of cerebrovascular disease and its associated risk factors, rise in the number of aging population,

Lab Automation Market to Reach Over USD 16 Billion in 2022

Underpinned by technology advancements, modern automated systems are already adept of a broad set of functions that have been previously carried out by manual, tedious labour. Instrumentation keeps on developing and is poised to perform tasks that were not even imaginable just some years ago. Initially used mostly by the big pharma and biotech companies,